Navigation Links
SFU duo's protein discovery links to cancer research
Date:7/26/2012

A Simon Fraser University graduate student's collaboration with her thesis supervisor on how a particular type of protein controls the growth of another protein could advance cancer research.

Their findings have just been published in the online July 26 issue of Current Biology, a CellPress journal.

Esther Verheyen, an SFU professor of molecular biology and biochemistry, has helped her Master's of Science student Joanna Chen uncover how Hipk can be manipulated to stop Yorkie from causing tissue overgrowth in flies.

Hipk is a protein kinase a type of enzyme that controls the activity of other proteins by depositing a phosphate residue on them.

Yorkie, known as Yap in humans, is another type of protein that induces the overgrowth of cell tissue in the eyes, legs and wings of flies. High levels of Yap are often found in human tumours.

In experiments on the fruit fly Drosophila, Verheyen and Chen first found that Hipk could cause overgrowths similar to those found on tissue with too much Yorkie.

The researchers then genetically generated flies in which there was a higher concentration of Yorkie but a lower concentration of Hipk present than normal in their organ and limb tissues.

"When we did that," says Chen, "Yorkie could not cause overgrowths anymore. We were able to show this need for Hipk to be present in a number of different fly tissues, such as the eyes, legs and wings."

"We found that Hipk could add a phosphate residue on Yorkie and we thought this might explain how Hipk could disrupt Yorkie's ability to cause an overgrowth," adds Verheyen. "This is a very common and reversible method of regulating protein activity, and, as a result, many essential developmental processes."

"Next we tested a mutant form of Hipk that had lost its ability to add phosphates to Yorkie," says Verheyen. "This form of Hipk could no longer prompt Yorkie to trigger cell proliferation or do anything to regulate cell growth.

"Hipk is the first discovery of a protein kinase that regulates Yorkie by stimulating its cell proliferation ability. All other known protein kinases either directly inhibit or block Yorkie from working."

Chen and Verheyen say their discovery is generating a lot of excitement in the molecular biology science community. "We have identified a factor that in flies is required for even overly active Yorkie to trigger overgrowth," explains Chen, who graduated in June. She begins working as a research assistant at the Vancouver Prostate Centre in August.

"By analogy, perhaps the human form of Hipk is needed in cells for overly active Yap (human form of Yorkie) to induce tumours. So if we can inhibit or reduce Hipk activity, it would allow us to prevent overgrowths and possibly cancer caused by excessive Yap in humans."

The two are now checking to see if this new cell growth regulation mechanism they've discovered is conserved across different species, including mice, which have similar Hipk proteins to humans.


'/>"/>

Contact: Carol Thorbes
cthorbes@sfu.ca
778-782-3035
Simon Fraser University
Source:Eurekalert

Related medicine news :

1. Protein build-up leads to neurons misfiring
2. Strong communication between brain and muscle requires both having the protein LRP4
3. Regulation by proteins outside cancer cells points to potential new drug target
4. Loss of protein SPDEF allows prostate cancer cells to gain foothold at possible sites of metastasis
5. The key (proteins) to self-renewing skin
6. Researchers discover rare leukemia-causing protein
7. PaleoMeal Organic Whey Protein Formula Improved According to Rockwell Nutrition
8. Moving 3D computer model of key human protein is powerful new tool in fight against cancer
9. Researchers reveal crucial immune fighter role of the STING protein
10. Protein residues kiss, dont tell
11. Overexpression of proteins 14-3-3 related to chemotherapy resistance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Guruji Mahendra ... 9th, 10th and 11th, 2016 in honor of his birthday on February 10th. ... happiness. Mahendra Trivedi is known by over 250,000 people from over 40 different ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women’s Excellence now ... the most minimally invasive approaches. , Women who have had multiple vaginal births ... factors include surgery to the pelvic floor, connective tissue disorders, and obesity. Women ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd Hobgood , ... medical and surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, ... non-surgical alternative for reduction of fat below the chin (aka the “double chin”). ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX ... warm color grades to their footage. A LUT is a Lookup Table that contains ... the corresponding color indicated by the table. By manipulating each pixel, LUT's can change ...
(Date:2/5/2016)... ... , ... Steven Tonkinson, 36, of Coconut Grove, Florida, ran the Miami Marathon ... 2003. This year, he ran all 26.2 miles with a green 25-pound ShelterBox strapped ... Heat. , This Sunday, while many are watching the Superbowl, Steven Tonkinson will strap ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... -- HemaFlo Therapeutics, Inc. announced today that the United States Patent ... covering the use of NephroFlow to treat acute kidney injury ... said, "We are pleased to secure our rights to such ... PhD, HemaFlo,s founder, said, "We are pleased to secure our ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ...
(Date:2/8/2016)... , Feb. 8, 2016  Dynatronics Corporation ... of advanced-technology medical devices and rehabilitation equipment for ... congratulates the Denver Broncos, football team for winning ... Cullimore Jr. , Chairman and Chief Executive Officer.  ... and we look forward to enhancing their athletic ...
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, ... therapeutic genome editing, announced that the U.S. Food ... Investigational New Drug (IND) application for SB-318, a ... therapy for Mucopolysaccharidosis Type I (MPS I). The ... Sangamo to initiate a Phase 1/2 clinical study ...
Breaking Medicine Technology: